GlassScriptPhysician profile
Jennifer D Okidegbe
NPI 1285997163
$8,958.12
in general payments reported to CMS, 2019-2025
20 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,519 · 2022: $1,031 · 2023: $2,206 · 2024: $2,582 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973 · Travel and Lodging: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,973.49 |
| Travel and Lodging | $2,434.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,852.05 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, Intracept Rf Probe |
| Abbott Laboratories | $2,483.20 | 2021-2025 | Proclaim |
| Nalu Medical, INC. | $1,820.41 | 2021-2024 | Nalu Neurostimulation System |
| Nevro Corp. | $306.46 | 2021 | |
| Abbvie INC. | $260.21 | 2021-2025 | |
| Spinal Simplicity, LLC | $256.28 | 2023-2025 | Ha Minuteman G3-R |
| Protega Pharmaceutials INC | $181.27 | 2025 | Roxybond |
| Vertos Medical, INC. | $169.66 | 2021-2022 | |
| Spr Therapeutics, INC | $139.18 | 2023 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $109.09 | 2021-2023 | Belbuca, Belbuca |
| Curonix LLC | $80.42 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.80 | 2021 | |
| Almatica Pharma LLC | $49.90 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $45.91 | 2025 | |
| Hikma Pharmaceuticals USA | $42.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $26.43 | 2023 | Durolane |
| Allergan, INC. | $24.99 | 2021 | |
| Biotronik Nro, INC. | $24.92 | 2025 | Prospera |
| Scilex Pharmaceuticals INC. | $17.83 | 2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $7.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Okidegbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.